In NSCLC, the overall incidence of MET exon 14-skipping mutations is approximately 3%–5.6%, and these mutations do not coexist with other NSCLC driver variations, like ALK or EGFR (Frampton et al., 2015; Heist et al., 2016). This evidence concerns the gene ALK and non-small cell lung carcinoma.